Trial reportAntimicrobial agents and chemotherapy2003
Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria.
Trial report in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.Antimicrobial agents and chemotherapy · 2015Trial
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.Lancet (London, England) · 2010Trial
- Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.European journal of clinical pharmacology · 2008Trial
- Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea.Antimicrobial agents and chemotherapy · 2006Trial
- Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.Antimicrobial agents and chemotherapy · 2004Trial
- CYP3A and CYP2D6 variability in antimalarial pharmacokinetics and pharmacogenetics across populations: a narrative review.Malaria journal · 2026Review
- Diagnosis and management of malaria in the intensive care unit.Journal of intensive medicine · 2024Review
- Synthesis of Artemether-Loaded Albumin Nanoparticles and Measurement of Their Anti-Cancer Effects.Biomedicines · 2022Article
- Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation.British journal of pharmacology · 2020Article
- Post-Marketing Surveillance of Quality of Artemether Injection Marketed in Southwest Nigeria.The American journal of tropical medicine and hygiene · 2020Article
- Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Antimicrobial agents and chemotherapy · 2014Article
- Efficacy and safety of artemether against a natural Fasciola hepatica infection in sheep.Parasitology research · 2008Article
- Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether.The American journal of tropical medicine and hygiene · 2008Article
- Artemisinins.Postgraduate medical journal · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
The antimalarial activity of artemether following oral or intramuscular administration in the plasma of 15 adults with acute uncomplicated Plasmodium falciparum malaria was measured by bioassay. The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008). Antimalarial activity in terms of the peak concentration in plasma (Cmax) after oral administration was a median of 16 times higher than that after intramuscular administration. The ratio of the area under the plasma concentration-time curve during the first 24 h (AUC(0-24)) after oral administration of artemether to the AUC(0-24) after intramuscular administration was a median of 3.3 (range, 1 to 11) (P=0.0001). In the acute phase, the time to Cmax was significantly shorter after oral administration (median, 1 h; range, 0.5 to 3.0 h) than after intramuscular administration (median, 8 h; range, 4 to 24 h) (P=0.001). Intramuscular artemether is absorbed very slowly in patients with acute malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.